Study guide

4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies

WHNP-BC Women's Health Nurse Practitioner Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction: About the WHNP-BC Exam

WHNP-BC Exam Facts, Blueprint & Study Plan

2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening

1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening

3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention

2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites

4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers

3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers

5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility

4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies

6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy

5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion

7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health

6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis

8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care

7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction

9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care

8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy

10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth

9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency

11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions

10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn

12 Chapter 11: Intrapartum Principles & Fetal Surveillance

11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies

13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications

12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs

14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions

13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold

15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders

14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders

16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health

15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis

17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care

16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care

18 Chapter 17: Assessment, Diagnostic Testing & Interpretation

17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities

19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing

18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation

20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities

19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care

4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies

Key Takeaways Explain This Topic AI

The ovulatory cycle has a variable follicular phase and a relatively fixed luteal phase of about 14 days; ovulation follows the LH surge by roughly 24–36 hours.

Puberty in girls usually begins with thelarche around age 10, and menarche follows about 2–3 years later at an average age of about 12.4 years in the United States.

In adolescents, normal cycles last 21–45 days with menses of 7 days or less; ACOG calls the menstrual cycle a vital sign.

The septate uterus is the most common Müllerian anomaly and the one most linked to miscarriage; it is treated by hysteroscopic septum resection when indicated.

Müllerian anomalies often coexist with renal anomalies, so a uterine anomaly should prompt renal imaging.

Last updated: October 2026

Clinically Important Pelvic Anatomy

Uterus: Fundus, body, isthmus (lower uterine segment in pregnancy), and cervix. Layers are the endometrium (functional and basal layers), myometrium, and serosa.

Blood supply: The uterine artery arises from the anterior division of the internal iliac artery and crosses over the ureter about 1.5–2 cm lateral to the cervix ("water under the bridge"), the main site of ureteral injury at hysterectomy. The ovarian artery arises directly from the aorta and runs in the infundibulopelvic ligament.

Ligaments: The round ligament runs from the uterine cornu through the inguinal canal to the labium majus (the source of round ligament pain in pregnancy). The cardinal and uterosacral ligaments provide apical support; their failure produces uterine or vault prolapse. The broad ligament is a peritoneal fold that carries the vessels.

Ovary and tube: The fallopian tube has interstitial, isthmic, ampullary, and fimbrial segments; fertilization and most ectopic pregnancies occur in the ampulla .

External genitalia: Bartholin glands lie at 4 and 8 o'clock in the vestibule; Skene glands are paraurethral.

The Hypothalamic-Pituitary-Ovarian Axis

The hypothalamus releases GnRH in pulses . Fast pulses favor LH; slow pulses favor FSH. Continuous GnRH (as with GnRH agonist therapy) downregulates the pituitary.

FSH recruits follicles and induces aromatase in granulosa cells; LH stimulates theca cells to make androgens, which granulosa cells convert to estradiol (the "two-cell, two-gonadotropin" model).

Estradiol gives negative feedback at low levels but positive feedback when it stays high (about 200 pg/mL for about 50 hours), triggering the LH surge .

Inhibin B (follicular phase) suppresses FSH; inhibin A and progesterone come from the corpus luteum.

The Ovarian and Endometrial Cycles

Phase Ovary Endometrium Hormones and Signs

Menses (days 1–5) New follicular cohort recruited Functional layer sheds Low estradiol and progesterone; FSH rises

Follicular (variable length) Dominant follicle selected Proliferative : glands and stroma grow Rising estradiol; clear, stretchy, abundant cervical mucus (spinnbarkeit, ferning)

Ovulation (about day 14 in a 28-day cycle) Follicle ruptures about 24–36 hours after the LH surge begins Early secretory changes LH surge; mittelschmerz in some women

Luteal (about 14 days) Corpus luteum secretes progesterone Secretory : glycogen-rich glands, stromal edema Progesterone raises basal body temperature 0.4–1.0 °F; thick cervical mucus; mid-luteal progesterone >3 ng/mL confirms ovulation

Without pregnancy, the corpus luteum regresses after about 14 days, progesterone falls, and menses begin. With pregnancy, hCG rescues the corpus luteum until the placenta takes over progesterone production at about 7–10 weeks (the luteal-placental shift).

Puberty and Menarche

Stage Typical Age Notes

Thelarche (breast budding, Tanner 2) About 10 years (often earlier in Black girls) Usually the first sign of puberty

  • Pubarche/adrenarche Shortly after thelarche Adrenal androgens drive pubic and axillary hair
  • Peak height velocity Before menarche Growth slows after menarche
  • Menarche Average about 12.4 years in the United States About 2–3 years after thelarche

Precocious puberty: Secondary sexual development before age 8 in girls warrants evaluation (bone age, LH/FSH, estradiol, and possibly a GnRH stimulation test and brain MRI).

Delayed puberty: No breast development by age 13, or no menarche by age 15 or within 3 years of thelarche, triggers an amenorrhea evaluation.

The adolescent cycle as a vital sign (ACOG): Cycles typically last 21–45 days , bleeding lasts 7 days or less , and changing a pad or tampon every 1–2 hours suggests heavy bleeding. Anovulatory cycles are common in the first 1–2 years after menarche, but bleeding that causes anemia needs evaluation for a bleeding disorder such as von Willebrand disease.

Menopause

Natural menopause occurs at an average age of about 51 . Menopause before 40 is premature (primary ovarian insufficiency), and menopause from 40 to 45 is early; both increase lifetime cardiovascular and bone risk.

Müllerian (Paramesonephric) Anomalies

The paired Müllerian ducts form the fallopian tubes, uterus, cervix, and upper vagina; they must fuse and then resorb the midline septum. The lower vagina and hymen come from the urogenital sinus. Defects are classified by ASRM's 2021 Müllerian Anomalies Classification.

Anomaly Embryologic Error Clinical Significance

Agenesis (MRKH syndrome) Ducts fail to develop Primary amenorrhea with normal breasts and pubic hair (46,XX); vaginal dilation therapy

Unicornuate uterus One duct fails to develop A rudimentary horn can bleed (cyclic pain) or host an ectopic pregnancy; strong renal agenesis link on the same side

Uterus didelphys Complete failure of fusion Two uteri and two cervices, often with a longitudinal vaginal septum; may cause obstructed hemivagina (OHVIRA) with ipsilateral renal agenesis

Bicornuate uterus Partial failure of fusion Indented fundal contour; malpresentation and preterm birth

Septate uterus Failure of septum resorption Most common anomaly and the one most associated with miscarriage ; hysteroscopic resection is considered after recurrent loss

Arcuate uterus Minimal residual septum Usually a normal variant

Transverse vaginal septum Failed fusion of Müllerian and sinus tissue Cyclic pain, hematocolpos above a blind vagina

Imperforate hymen Failed canalization of the urogenital sinus Bulging bluish membrane at the introitus, cyclic pain, urinary retention; hymenotomy

DES-related (T-shaped) uterus In utero diethylstilbestrol exposure Preterm birth, ectopic pregnancy, vaginal clear cell adenocarcinoma

Diagnosis: 3D transvaginal ultrasound or MRI best shows the external fundal contour (smooth or minimally indented in septate; deeply indented in bicornuate). Hysterosalpingography alone cannot reliably tell septate from bicornuate. Because the kidneys and Müllerian ducts develop together, renal ultrasound is recommended when a uterine anomaly is found.